Leerink Partners on WAVE Life Sciences (WVE) after obesity data disappoints: selloff 'very overdone'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
RBC on WAVE Life Sciences (WVE): 't we continue to see a molecule that is pharmacologically active and remain optimistic'
March 27, 2026 5:04 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $27.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "The news: WVE reported updated INHBE data. At 240 mg, company reported 0.3/0.9% reductions in body weight (at 3/6 months), 8/14% reductions in visceral fats, 5/5% reduction in total fat and 2/2% increase in lean mass. At 400 mg, weight loss data at 3 months was not shared (we assume negligible), but WVE notes 5% reduction in visceral fats and 0.7% reduction in total fats. On lack of weight loss, WVE notes that the patients enrolled have materially... More
WAVE Life Sciences (WVE) PT Lowered to $39 at Clear Street, 'we think ‘007 should find its optimal patient population'
March 26, 2026 4:21 PM EDTClear Street analyst Bill Maughan lowered the price target on WAVE Life Sciences (NASDAQ: WVE) to $39.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "We are updating our model to reflect peak 15% penetration into the Rx-treated US obesity market (20% Europe) (prev. 20% and... More
B.Riley on WAVE Life Sciences (WVE): 'a ~60% intraday selloff that, in our view, is significantly overdone'
March 26, 2026 12:23 PM EDTB.Riley analyst Madison El-Saadi reiterated a Buy rating and $37.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "We reiterate our Buy rating on WVE ($37 PT under review) following this morning's mixed INLIGHT Ph1 6-month (240 mg) and 3-month (400 mg) data that... More
Jefferies on WAVE Life Sciences (WVE): 'near-term pressure on stock'
March 26, 2026 9:37 AM EDTJefferies analyst Roger Song reiterated a Buy rating and $28.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "Bottom line. We see the update validated INHBE fat-targeting MOA showing durable fat loss from 3mo to 6mo while preserving muscle, resulting in a net weight loss. However, given Ph1 population had lower BMI vs. that from comp... More
